A Hybrid Closed-Loop Insulin Delivery System for the Treatment of Type 1 Diabetes

Image courtesy of Medtronic
Authors: Vicki Foerster, Melissa Severn

Cite as: A hybrid closed-loop insulin delivery system for the treatment of type 1 diabetes. Ottawa: CADTH; 2017 June. (CADTH issues in emerging health technologies; issue 155)

Acknowledgments: CADTH thanks the external reviewers who kindly provided comments on an earlier draft of this bulletin.

ISSN: 1488-6324 (online)

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While CADTH has taken care to ensure that the information prepared by it in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. You are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
Summary

• Because their bodies no longer produce enough insulin, people with type 1 diabetes mellitus must check their blood glucose — or blood sugar — levels several times a day and then calculate and inject an appropriate insulin dosage.

• Wearable systems, sometimes referred to as an “artificial pancreas,” are now available to replicate some of the functions of the pancreas in controlling insulin delivery.

• The MiniMed 670G is currently the only hybrid closed-loop system licensed for commercial use.

• Available evidence supports the safety of the MiniMed 670G system for individuals with type 1 diabetes who are 14 years of age and older. Several further studies are underway, including a study in children and a larger randomized controlled trial.

• The manufacturer, Medtronic, expects the MiniMed 670G will be available in the US in the spring of 2017. Its availability in Canada is not yet known.

Issue

In people with type 1 diabetes, the pancreas either does not produce any insulin, or it does not produce enough insulin. People with type 1 diabetes need to take insulin daily to maintain blood glucose — or blood sugar — levels within the target range.\(^1\) They must frequently check glucose levels using a finger-stick test or a continuous glucose monitor and then determine the correct insulin dose to administer. Taking too much insulin can lead to hypoglycemia, or low blood sugar — a particular risk when this occurs overnight. Taking too little insulin can lead to hyperglycemia, or high blood sugar, and diabetic ketoacidosis — a build-up of chemicals called ketones that are produced when the body uses fat instead of sugar to make energy.\(^1,2\) These conditions, as well as high and low swings in blood glucose levels, are associated with increased morbidity and mortality.\(^1\)

Wearable systems are available for the continuous management of type 1 diabetes. These systems are intended to control blood glucose during particularly challenging times, such as overnight, at meal times, and when exercising.\(^3\)

Automating the delivery of insulin in wearable systems combines three functions:

• continuous glucose monitoring
• insulin delivery via a pump
• control of insulin using specific algorithms (a set of rules used by a computer program to make calculations).\(^4\)

The continuous glucose monitor sends glucose values to the insulin pump, and an algorithm determines the amount of insulin needed based on the sensor values and the amount of active insulin in the individual.\(^4,5\) Integrating these three functions creates a closed-loop system, without any intervention from the user — in other words, an artificial pancreas.\(^4,5\)

In contrast, a hybrid closed-loop system still needs user interventions (for example, fast-acting bolus insulin doses taken at meal times).\(^3\)

One hybrid closed-loop insulin delivery system, the MiniMed 670G (Medtronic, Dublin, Ireland), is now available in the US.

The Technology

The MiniMed 670G is a hybrid, closed-loop, insulin delivery system made up of various components that perform different functions.\(^6\)

• The Guardian Sensor, which is inserted under the skin using a small insertion device and taped in place for a single-use, seven-day period. It measures glucose levels in the fluid surrounding the cells below the skin (interstitial fluid). The sensor does not replace finger-stick tests for determining insulin requirements for meals and activities. It also requires a minimum of two finger-stick calibrations against the system's glucose metre every day; four calibrations are recommended.
• The CONTOUR NEXT LINK 2.4 glucose metre, with test strips, for finger-prick capillary blood sampling to calibrate the system. Glucose values are automatically transmitted to the insulin pump.

• The MiniMed 670G insulin pump — a waterproof, battery-operated, rate-programmable, micro-infusion pump that delivers insulin from a reservoir.

• The Guardian Link Transmitter, in conjunction with the glucose sensor, which collects and wirelessly transmits interstitial glucose values to the insulin pump. The MiniMed 670G system can store up to 90 days of pump and glucose sensor data.

The system can be used in either automatic or manual mode, but in both modes the user must manually enter the estimated carbohydrates to be consumed at meals and accept mealtime insulin boluses suggested by the system. In automatic mode, the system uses an algorithm to automatically adjust basal insulin (insulin that keeps your blood sugar stable between meals or during sleep) delivery in response to fluctuations in interstitial glucose levels. In manual mode, the user can set the pump to suspend activity at or before low glucose values. Insulin delivery will automatically suspend activity when the glucose level drops or is predicted to drop to a selected threshold (e.g., low blood glucose in the 2.8 mmol/L to 5.0 mmol/L range). Remote transmission of data from the system and monitoring via telemedicine is possible.

Availability
The MiniMed 670G system is not yet licensed by Health Canada.

In the US, the MiniMed 670G system received FDA approval in September 2016. The system received a priority review because it is a novel technology and availability was considered to be in the best interests of patients. The FDA approval states that the system is intended for continuous delivery of basal insulin at user selectable rates, and administration of insulin boluses in user selectable amounts, for the management of type 1 diabetes in persons aged 14 and older. Medtronic plans to market the system in the US in the spring of 2017, and outside the US later in 2017.

Cost
In Canada, although the purchase costs of the system are not yet known, Medtronic estimates that the annual operating costs will be in the C$8,500 to C$9,500 range, excluding the cost of insulin, and will be comparable to the operating costs of existing insulin pump technologies with continuous glucose monitoring. (Ruth Pichora, Medtronic, Diabetes Canada, Brampton, ON: personal communication, 2017 Mar 7).

Who Might Benefit?
Currently, the MiniMed 670G is intended for use by people older than 14 who have type 1 diabetes and require at least eight units of insulin daily. At this time, it is not intended for use by children under the age of seven because they usually require less than this amount of insulin. However, there are efforts underway in the US to expand the age range to children younger than 14 years of age (Ruth Pichora: personal communication, 2017 Mar 7). People with significant nocturnal hypoglycemia, or hypoglycemia unawareness, could particularly benefit from this type of technology. Because the system requires finger-stick tests for calibration, and before meals and activities, it is not suitable for patients unwilling or unable to do frequent finger-stick glucose measurements.

Current Practice
The Diabetes Control and Complications Trial (1983 to 1993) revolutionized the treatment of type 1 diabetes by showing that intensive glycemic control, beginning as soon as possible after diagnosis, prevents or delays diabetes-related complications of the eyes, kidneys, and nerves. A large, more recent study found that higher average blood glucose levels and increased proteinuria, which is abnormally high levels of protein in the urine, were major risk factors for death, demonstrating how important glycemic control is for contributing to longer and healthier lives for people with type 1 diabetes.

The current approach to managing diabetes is for a multidisciplinary team, using a patient-centred approach, to set glycemic targets according to individual circumstances (e.g., diet, age, weight, hypoglycemia awareness status, ability for self-management, patient preferences), and to offer structured educational programs to promote patient empowerment. Insulin is administered either by multiple daily injections or by
an insulin pump that delivers a continuous subcutaneous insulin infusion. Long-acting and ultra-long-acting insulins can be combined with rapid-acting insulins to provide effective basal bolus therapy to reflect physiological insulin secretion.

The Evidence

Currently, the evidence for the effectiveness of the MiniMed 670G device consists of one small randomized controlled trial, reported in a conference abstract and a prospective before-and-after cohort study submitted to the FDA (Table 1).

The randomized controlled trial described the safety and efficacy of a preliminary algorithm for the MiniMed 670G in 21 teens and young adults with type 1 diabetes at a diabetes camp. Patients were randomized to receive the MiniMed 670G or the MiniMed 530G (an earlier Medtronic system), with a suspension threshold of 3.3 mmol/L, over six days and nights.

The prospective before-and-after study, funded by Medtronic, focused on safety. Although some efficacy results were provided, the study was not designed to show efficacy. The study was carried out at 10 centres (nine in the US and one in Israel) from June 2015 to March 2016. The study enrolled 126 patients with type 1 diabetes; 123 completed the study. A two-week baseline run-in period was followed by a three-month study period. Safety end points were: incidence of severe hypoglycemia and diabetic ketoacidosis, serious adverse events, and device-related serious or unanticipated adverse events. Efficacy end points included time in open- versus closed-loop systems; percentage of sensor glucose values below, within, and above the target range (3.9 mmol/L to 10.0 mmol/L); changes in glycated hemoglobin (A1C), insulin requirements, and body weight; and measures of glycemic variability.

Clinical Efficacy and Effectiveness

Results of the randomized controlled trial showed that both the MiniMed 670G system and the MiniMed 530G system worked well during the day, with similar glucose values within the target range of 3.8 mmol/L to 10.0 mmol/L. However, the MiniMed 670G was associated with less hypoglycemia overnight — experienced by 1.3% of patients with the MiniMed 670G versus 5.2% with the control device.

Efficacy data from the prospective before-and-after study (Table 1) included a drop in mean A1C levels and an increase in the percentage of time that blood glucose was in the target range; no statistics were provided.

Safety

According to the FDA safety summary, two potential device-related serious adverse events are: diabetic ketoacidosis from high blood glucose due to inadequate or suspended insulin delivery, and severe hypoglycemia from over-delivery of insulin. Potential device-related, non-serious events include: skin irritation or redness, infection, pain or discomfort, bruising, swelling, rash, bleeding, induration (hardening) of the skin, and allergic reactions to the skin adhesives.

The prospective before-and-after study reported few serious or device-related adverse events. During 12,389 patient-days, there were no device-related serious adverse events (episodes of severe hyperglycemia or diabetic ketoacidosis). However, there were 28 device-related adverse events that were resolved at home. These included 17 episodes of severe hyperglycemia (glucose greater than 16.6 mmol/L, with blood ketones greater than 0.6 mmol/L or accompanied by symptoms of nausea, vomiting, or abdominal pain), six episodes of less severe hyperglycemia, four reports of skin irritation, and one report of rash. No adverse events were reported in the small randomized controlled trial.

Cost-Effectiveness

A recent cost-effectiveness analysis performed from a UK National Health Service perspective, used technologies that combined sensor-augmented insulin pump therapy with continuous glucose monitoring (referred to as ‘the newer paradigm’) compared with insulin pump therapy with patient self-monitoring. Results showed the newer paradigm was associated with higher average quality-adjusted life expectancy (18 quality-adjusted life-years versus 15 quality-adjusted life-years), and higher life expectancy (24 years versus 22 years). But there were also higher average lifetime direct costs equivalent to C$206,000 versus C$145,000, leading to an incremental cost-effectiveness ratio equivalent to C$20,000 per quality-adjusted life-year gained (all figures rounded).
Upcoming Research
At least four studies of the MiniMed 670G are underway or planned (see Table 2). Two are of particular interest, both of which are funded by the manufacturer:

• The Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes is investigating the safety of the MiniMed 670G in children two to 13 years old.20
• The Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home (NCT02748018) is planned as a randomized, parallel group study, with recruitment of 1,500 people with type 1 diabetes. The trial will test three MiniMed 670G settings against control groups, using multiple-dose injections, insulin pump technology alone, and sensor-augmented pump technology.21

Concurrent Developments
A recent UK horizon scanning report on artificial pancreas devices identified 18 closed-loop systems in various stages of development.4 All were in clinical trials prior to potential commercialization, although only five of the devices were expected to be marketed in the European Union by 2018.4 Of particular interest is a technology from Boston — the Physiologic Insulin Delivery with Adaptive Basal (PIDAB) — that eliminates the need for pre-meal carbohydrate calculations, as it includes a meal identification algorithm to deliver insulin in several boluses: within the first 15 to 30 minutes of a meal, at 30 to 45 minutes, and at 60 minutes.4

“Surveys of potential users of closed-loop insulin delivery systems have found considerable interest in using these technologies.”

Glucagon has also been a focus of recent diabetes research. Glucagon is a hormone produced by the pancreas to correct hypoglycemia. One approach to the management of type 1 diabetes is a dual-hormone system that automatically delivers both insulin and glucagon.3,22 In dual-hormone systems, the addition of glucagon could be used to reduce hypoglycemia or mean glucose concentrations in one of two ways: by adding glucagon to reduce hypoglycemia without increasing the level of insulin delivery, or by delivering insulin more aggressively and counteracting it with glucagon when necessary.3 However, the use of glucagon is limited by problems that arise following reconstitution, as it forms amyloid fibrils, or fibres, that can clog or obstruct pump hardware.3

With respect to curative therapy for type 1 diabetes, research on pancreas or islet cell transplantation is underway but has been limited by organ availability and the risks associated with immunosuppression. The quest for a bioartificial pancreas is also ongoing, as this would alleviate the need for immunosuppression.3,22 In a bioartificial pancreas, pancreatic islets (porcine, human, or derived from embryonic stem cells) are enclosed in a biocompatible agent to allow nutrient, insulin, and glucose exchange; human trials with this method are underway.3,22 (Another bulletin in this series looks at the evidence to date on ViaCyte’s islet cell replacement therapy (ViaCyte, San Diego, California.)

Implementation Issues
Uptake
Surveys of potential users of closed-loop insulin delivery systems have found considerable interest in using these technologies. For example:

• In a survey of people with type 1 diabetes in England, 240 of 266 respondents (90%) said they were extremely or highly likely to use a fully-automated, 24-hour artificial pancreas if it was available.24 The researchers noted that, despite perceived potential disadvantages, there was a strong need for a device that will minimize the burden of disease, facilitate improved psychosocial functioning, and improve quality of life.
• Similarly, in a French study that presented information on the artificial pancreas to 101 people with type 1 diabetes, most patients expressed a desire to have such a system, and the proportion noting it was extremely likely they would replace their current insulin pump with an artificial pancreas system rose from 24% to 41% after the information session.25 Two factors were associated with an interest in using an artificial pancreas: recent disease onset, and current use of an insulin pump rather than multiple daily injections.
In Italy, a study of the attitudes of 27 parents of children with type 1 diabetes found that most parents were supportive of the artificial pancreas model. The perceived advantages of the model were stable glucose regulation, relief of daily concerns, and reduced need for nocturnal monitoring, with patients being confident about the positive impact on disease control and their ability to use the system. Perceived disadvantages were the need to constantly deal with a bulky device and the risk of technical error. All parents stated their intention to use the technology when it became available.

Regarding physician attitudes, a survey of 105 European endocrinologists indicated positive intentions toward prescribing the artificial pancreas (mean score of 5.5 on a 7-point Likert scale).

Despite the interest of parents, patients, and physicians, experts have noted that earlier advances, such as continuous glucose monitoring, have not yet become standard reimbursed diabetes therapies for a number of reasons:

• Rapid changes, such as exercise and meals, make continuous glucose monitoring less accurate than capillary finger-stick samples because of the lag time between capillary and interstitial readings.
• Sensors require frequent replacement.
• Sensors must be inserted into the skin.
• Sensor accuracy is not always optimal, particularly in the hypoglycemic range.
• Recalibrations with finger-prick samples are still required.
• An annual cost of continuous glucose monitoring in the US is US$3,000 to US$4,300. Medtronic estimates the cost of continuous glucose monitoring, based on the use of 60 sensors per year, is approximately C$3,600 (Ruth Pichora: personal communication, 2017 Mar 7).

The cost of the devices and their annual operating costs may be a financial burden for people with diabetes and their families. Decisions about the public funding of these technologies will become important.

Methods — Literature Search Strategy
A limited literature search was conducted using the following bibliographic databases: MEDLINE, PubMed, Embase, and the Cochrane Library. Grey literature was identified by searching relevant sections of the Grey Matters checklist (cadth.ca/grey-matters). No methodological filters were applied. The search was limited to English-language documents published between January 1, 2015, and January 19, 2017. Conference abstracts were included in the search results. Regular alerts updated the search until project completion; only citations retrieved before March 6, 2017 were incorporated into the analysis.

Final Remarks
Authors of the recent UK briefing on artificial pancreas technologies noted that widespread adoption will depend on evidence that these systems are safe and effective in real-life settings over longer periods of time, and that they are cost-effective and acceptable to users.
Table 1: Characteristics and Findings of Included Studies

<table>
<thead>
<tr>
<th>First Author (Year), Site, Country, Funder</th>
<th>Study Design and Study Exclusions</th>
<th>Patient Characteristics</th>
<th>Intervention and Comparator</th>
<th>Study Duration and Clinical Outcomes Tracked</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ly et al. (2015), Stanford University, CA, US14 Conference abstract Funder NR (6 of 10 authors were employed by Medtronic)</td>
<td>Prospective RCT at a DM camp Study exclusions: NR</td>
<td>n = 20 patients with T1DM; sex distribution NR, mean age 18.6 years (SD 3.7), mean DM duration 9.1 years (SD 4.7), mean total daily insulin 0.8 U/kg (SD 0.2), mean A1C 8.6% (SD 1.5%)</td>
<td>MiniMed 670G (intervention) or 530G with threshold suspend at 3.3 mmol/L (control)</td>
<td>Duration: 6 days and nights at DM camp Outcomes: % of time in closed (vs. open) loop mode, % of time glucose was in target range (3.9 to 10.0 mmol/L) daytime (7 a.m. to 11 p.m.) and overnight (11 p.m. to 7 a.m.)</td>
<td>Safety: NR Efficacy: • Patients in the 670G group remained in closed loop 93% of the time. • Glucose in the target range, daytime, was similar between groups; 68.5% vs. 69.3%, control vs. 670G, respectively, P = 0.89. • Glucose in the target range, overnight, had less nocturnal hypoglycemia; &lt; 3.9 mmol/L in the 670G group, P = 0.003.</td>
</tr>
<tr>
<td>Bergenstal et al. (2016), International Diabetes Center, Minneapolis, MN, US6,15-18 NCT02463097 Funder: Medtronic</td>
<td>Prospective observational before-and-after safety study at 10 centres (9 in US, 1 in Israel), June 2015 to March 2016. Many study exclusions including 2 or more episodes of severe hypoglycemia or DKA in previous 6 months</td>
<td>n = 126 patients with T1DM (of which 3 did not complete); 56% women, mean age 37.8 years (SD 16.5, range 14 to 75), mean DM duration 21.7 years, mean total daily insulin 47.5 U (SD 22.7 U), mean A1C 7.4% (SD 0.9%)</td>
<td>MiniMed 670G (no comparator)</td>
<td>Duration: 2-week run-in, then 12-week study period including a 6-day hotel stay: 12,389 patient-days Outcomes: (a) Safety: severe hypoglycemia, DKA, SAEs, device-related SAEs and AEs (b) Effectiveness: % of time in closed- (vs. open-) loop mode, A1C levels, daily insulin dose, glycemic variability</td>
<td>Safety: • No episodes of severe hypoglycemia or DKA • No device-related SAEs. 4 SAEs not related to the system (appendicitis, bacterial arthritis, worsening rheumatoid arthritis, Clostridium difficile diarrhea) • 28 device-related AEs that resolved at home, including 17 episodes of severe hyperglycemia (glucose &gt; 16.0 mmol/L) due to the infusion set, software or hardware issues, or sensor issues • 117 AEs not related to the system including 7 episodes of severe hyperglycemia due to intercurrent illness or other non-system causes Efficacy: • % of time in closed-loop mode: median 87.2% • A1C levels: dropped from a mean of 7.4% to 6.9% • Daily insulin dose: increased from 47.5 U to 50.9 U • % of glucose in target range: increased from 66.7% to 72.2%</td>
</tr>
</tbody>
</table>

A1C = glycated hemoglobin; AE = adverse event; CA = California; DKA = diabetic ketoacidosis; DM = diabetes mellitus; MN = Minnesota; NR = not reported; RCT = randomized controlled trial; SAE = serious adverse event; SD = standard deviation; T1DM = type 1 diabetes mellitus; U = unit; vs. = versus.
<table>
<thead>
<tr>
<th>Study Identifier, Country, Dates, Sponsor</th>
<th>Study Status and Phase</th>
<th>Study Design and Main Study Exclusions</th>
<th>Patient Group</th>
<th>Intervention</th>
<th>Follow-up and Clinical Outcomes Tracked</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02660827²⁰ International — 10 centres (9 in US, 1 in Israel) April 2016 to April 2018 Medtronic</td>
<td>Recruiting Phase IV</td>
<td>Prospective cohort safety study at home in children with T1DM on insulin pump therapy, aged 2 to 13. Exclusions: &gt; 2 episodes of severe hypoglycemia or DKA in past 6 months</td>
<td>n = goal of 120 children with T1DM</td>
<td>670G system (primarily testing the algorithm)</td>
<td>Follow-up = 3 months after a 2-week run-in period Safety: Event rates of severe hypoglycemia and DKA Efficacy: Change in A1C</td>
</tr>
<tr>
<td>NCT03017482²⁹ US (Stanford University) February 2017 to February 2019 Stanford University</td>
<td>Not yet open for recruitment</td>
<td>Prospective cohort study in patients starting on 670G (aged 7 to 13; i.e., not currently approved for use by the FDA). Exclusions: Pregnant or planning pregnancy in next 12 months</td>
<td>n = goal of 100 people aged 7+ with T1DM who are planning to start using the 670G</td>
<td>670G system</td>
<td>Follow-up = 12 months Safety: Event rates of severe hypoglycemia and DKA by 12 months Efficacy: % of time patients use closed-loop by 6 months (goal &gt; 70%); % of time in range (3.9 mmol/L to 10.0 mmol/L)</td>
</tr>
<tr>
<td>NCT03040414³⁰ International — 10 centres (4 in US and 1 each in Germany, Israel, Slovenia) December 2017 to June 2020 HealthPartners Institute, NIDDK, Medtronic</td>
<td>Not yet open for recruitment</td>
<td>Prospective randomized, open-label crossover study comparing two automated insulin delivery system algorithms (670G vs. next-generation 690 that uses fuzzy logic). Exclusions: 1+ episode of DKA in past 6 months and multiple others</td>
<td>n = goal of 112 teens and young adults, aged 14 to &lt; 30 years, with T1DM</td>
<td>670G versus next-generation 690 that uses a fuzzy logic algorithm — 12 weeks, 4 week washout, 12 weeks alternative system</td>
<td>Follow-up = 5 months Safety: Event rates of severe hypoglycemia and DKA Efficacy: % of time blood glucose is &gt; 10.0 mmol/L from 7 a.m. to 11 p.m., in target range (3.9 mmol/L to 10.0 mmol/L), and &lt; 3.9 mmol/L QoL and DM technology attitudes questionnaires</td>
</tr>
<tr>
<td>NCT02748018³¹ International — up to 70 centres in the US, Canada, Europe, and elsewhere January 2017 to August 2020 Medtronic</td>
<td>Not yet open for recruitment Phase III</td>
<td>Prospective, multi-centre, randomized, parallel adaptive study in T1DM in the home setting. Exclusions: multiple</td>
<td>n = goal of 1,500 people, aged 7 to 75 years, with T1DM</td>
<td>4 study groups: MDI 670G 670G without the glucose sensor 670G without low management suspend</td>
<td>Follow-up = 6 months Safety: Event rates of severe hypoglycemia and DKA Efficacy: % of time blood glucose is in the target range (3.9 mmol/L to 10.0 mmol/L), and &lt; 3.9 mmol/L; change in A1C</td>
</tr>
</tbody>
</table>

A1C = glycated hemoglobin; DKA = diabetic ketoacidosis; DM = diabetes mellitus; MDI = multiple daily injections; NIDDK = National Institute of Diabetes and Digestive and Kidney Diseases; QoL = quality of life; T1DM = type 1 diabetes mellitus; vs. = versus.
References


